Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat- and FYVE domain-containing protein 4 (WDFY4)
- Target
- WDFY4
- Molecular classification
- Other (specifically: BEACH-domain containing protein, WD repeat protein, FYVE domain–containing protein)
01
Overview
WD repeat- and FYVE domain-containing protein 4 (WDFY4) is a large cytoplasmic scaffold protein characterized by the presence of BEACH, PH, WD40, and FYVE domains. It is predominantly expressed in immune organs and is essential for antigen cross-presentation by CD8α+ classical dendritic cells, thereby regulating CD8+ T cell responses critical for antiviral and antitumor immunity. WDFY4 is also involved in B-cell development, non-canonical autophagy, and vesicular trafficking, functioning as a molecular scaffold for protein complexes associated with endosomes and the endoplasmic reticulum. Genetic variants in WDFY4 are linked to autoimmune disorders and have been implicated as prognostic markers in several cancers, although no drugs are currently known to target this protein directly.
- Other names
- WDFY4WD repeat- and FYVE domain-containing protein 4C10orf64KIAA1607FLJ45748Em:AC060234.3
02
Mechanism of action
Not applicable; no known drug modulators
03
Biological functions
Cross-presentation of antigens by dendritic cellsRegulation of B-cell growth and developmentParticipation in antigen processing and presentationInvolvement in CD8+ T cell activationModulation of apoptosis (especially reactive oxygen species-induced apoptosis of CD8+ T cells)Regulation of vesicular trafficking and endosomal targetingNon-canonical autophagic activity in B cells
04
Disease associations
Autoimmune diseases (including systemic lupus erythematosus, rheumatoid arthritis, primary biliary cholangitis, dermatomyositis, and rapidly progressive interstitial lung disease)Cancer (prognostic factor, especially in lung cancer, glioma, renal cell carcinoma, and squamous cell carcinoma)Other immune-mediated diseases (due to effects on T cell priming and immune response)
05
Biomarkers
Autoimmune disease risk (WDFY4 genetic variants as susceptibility loci for SLE, RA, etc.)Prognostic marker in various cancers (expression levels or methylation status)Association with anti-MDA5 antibody positive dermatomyositis (especially the rs7919656 variant)
Beyond the preview
Go deeper on WD repeat- and FYVE domain-containing protein 4 (WDFY4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WD repeat- and FYVE domain-containing protein 4 (WDFY4).